Ramucirumab as First-Line Therapy in Combination with Cisplatin and Fluoropyrimidine in Patients with Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma (RAINFALL): A Global, Randomised, Double-Blinded, Placebo-Controlled, Phase 3 Trial
Year: 2018
Type: preprint
Study designs: Randomized Controlled Trial, Clinical Trial
Source: SSRN Electronic Journal
DOI: 10.2139/ssrn.3221440
Authors: Charles Fuchs, Kohei Shitara, Maria Di Bartolomeo, Sara Lonardi, Salah-Eddin Al-Batran, Eric Van Cutsem, David H. Ilson, Maria Alsina, Ian Chau, Jill Lacy, Michel Ducreux, Guillermo Ariel Mendez, Alejandro Molina Alavez, Daisuke Takahari, Wasat Mansoor, Peter Enzinger, Vera Gorbounova, Zev A. Wainberg, Susanna Hegewisch-Becker, David Ferry, Ji Lin, Roberto Carlesi, Mayukh Das, Manish A. Shah, RAINFALL Study Group
Institutions: Yale Cancer Center, Yale University, Smilow Cancer Hospital, National Cancer Center Hospital East, Fondazione IRCCS Istituto Nazionale dei Tumori, Istituto Oncologico Veneto, Institute of Clinical Cancer Research, Krankenhaus Nordwest, KU Leuven, Memorial Sloan Kettering Cancer Center, Universitat Autònoma de Barcelona, Vall d'Hebron Institute of Oncology, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, Université Paris-Saclay, Institut Gustave Roussy, Favaloro University, Fundacion Favaloro Hospital Universitario, Favaloro Foundation, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, The Christie NHS Foundation Trust, Harvard University, Russian Cancer Research Center NN Blokhin, University of California, Los Angeles, Ronald Reagan UCLA Medical Center, UCLA Medical Center, Eli Lilly (United States), Eli Lilly (Italy), Cornell University, Weill Cornell Medicine
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4245477385